Literature DB >> 3160301

Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.

S M Smith, R H Eng.   

Abstract

Ciprofloxacin, a carboxy quinolone antibiotic with a broad spectrum of activity, was tested against 54 strains of methicillin-resistant Staphylococcus aureus. The ciprofloxacin MICs for 50 and 90% of the isolates were 0.25 and 0.5 micrograms/ml, respectively, and its MBC for 90% of the isolates was 1.0 microgram/ml. Killing kinetic studies were conducted in vitro with ciprofloxacin and vancomycin individually and in combination. The results of these studies showed that ciprofloxacin at 2 micrograms/ml and vancomycin at 10 micrograms/ml decreased the number of organisms by approximately 1.5 log10 after 6 h. The combination of ciprofloxacin plus vancomycin did not alter the rate of killing over that achieved by ciprofloxacin alone. The in vitro killing of resistant staphylococci was rapid, and the potential use of ciprofloxacin for infections caused by methicillin-resistant S. aureus should be further explored.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3160301      PMCID: PMC180133          DOI: 10.1128/AAC.27.5.688

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  A novel type of resistant bacteria induced by gentamicin.

Authors:  K Li; J J Farmer; A Coppola
Journal:  Trans N Y Acad Sci       Date:  1974-05

2.  Methicillin-resistant staphylococcemia: bacteriological failure of treatment with cephalosporins.

Authors:  J F Acar; P Courvalin; Y A Chabbert
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

3.  Mechanisms responsible for plasma levels of nafcillin lower than those of oxacillin.

Authors:  A C Kind; T E Tupasi; H C Standiford; W M Kirby
Journal:  Arch Intern Med       Date:  1970-04

4.  The emergence of methicillin-resistant Staphylococcus aureus.

Authors:  R P Wenzel
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

5.  Treatment of infections due to methicillin-resistant Staphylococcus aureus.

Authors:  C Watanakunakorn
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

6.  Vancomycin therapy for methicillin-resistant Staphylococcus aureus.

Authors:  T C Sorrell; D R Packham; S Shanker; M Foldes; R Munro
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Penetration of antibiotics into vegetation of heart valves: a mathematical model.

Authors:  R H Eng; P Parken; F Tecson-Tumang
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

Review 9.  Vancomycin.

Authors:  R Fekety
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

Review 10.  Treatment failures secondary to in vivo development of drug resistance by microorganisms.

Authors:  B Sugarman; E Pesanti
Journal:  Rev Infect Dis       Date:  1980 Mar-Apr
View more
  22 in total

1.  Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus.

Authors:  K Ubukata; N Itoh-Yamashita; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria.

Authors:  R H Eng; F T Padberg; S M Smith; E N Tan; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

3.  Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations.

Authors:  S M Smith; R H Eng; F Tecson-Tumang
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

4.  In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

5.  The place of quinolones in antibacterial therapy in hospitals.

Authors:  R P Mouton
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

6.  In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  In vitro activity of AT-4140 against clinical bacterial isolates.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  In vitro susceptibilities of four species of coagulase-negative staphylococci.

Authors:  R J Fass; V L Helsel; J Barnishan; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

9.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.

Authors:  Cornelia B Landersdorfer; Martina Kinzig; Friedrich F Hennig; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel; Johannes Gusinde
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.